Target therapies have become an important component of the treatment of many cancers, with significant evidence of a gain in survival in their use, but at the same time, with increasing concern about their ability to cause a wide spectrum of secondary cardiovascular adverse events (left ventricular dysfunction, heart failure, hypertension, ischaemic heart disease, QT prolongation, sudden cardiac death), partly because of an increased use of combination therapies and a growing population with cardiovascular risk factors. The following article summarises the recent data in the literature on the epidemiology and pathophysiology of cardiotoxicity induced by different target drugs, as well as strategies for patient management before, during and after antineoplastic treatment, early diagnosis of cardiovascular adverse events, with particular attention on the role of echocardiography. The delicate balance between effective cancer therapy and the risk of secondary cardiovascular disease that could affect the gain of survival, requires a profound collaboration between oncologists and cardiologists, with the aim of creating a personalised therapy for the patient and their illness.
1 Simultaneously, with the improvement in the management of cancer patients and prolonged survival, cardiotoxicity has become increasingly important, as the adverse effects on the heart may create new challenges in the long-term management of the patients, reducing the effectiveness of treatment and survival, due to the appearance of comorbidities.
Chemotherapy-Related Left Ventricular Dysfunction and Heart Failure
over the last 20 years, considerable progress has been made in the management of cancer due to the introduction of targeted molecular therapies.
2 however, even these new target drugs have been shown to have a cardiotoxic potential, especially when used as combination therapies, by inhibition of transduction pathways in normal or non-cancerous cells.
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Monoclonal Antibodies
Trastuzumab is a humanised monoclonal antibody against the human epidermal growth factor receptor (hER2), a tyrosine kinase receptor overexpressed at the time of diagnosis in 15 % of breast cancer (Bc) and up to 20-30 % of metastatic Bc, 4 which is associated with more aggressive disease, poor response to therapy and survival. Trastuzumab is used to treat Bc cells that overexpress hER2, increasing the overall survival, but at the same time, the risk of cardiotoxicity. 5,6 a 2001 pivotal study reported a gain of survival of 4.8 months when trastuzumab is administered with anthracycline; however, 27 % of patients who received the combination therapy developed signs of hF (16 % were in New York heart association
[NYha] class iii-iV). 4 Pooled data on the use of trastuzumab have reported an incidence of lVd of 3-7 % (trastuzumab alone), up to 27 % when administered with anthracyclines; 5,7 while adjuvant trastuzumab after anthracyclines and paclitaxel is associated with an incidence of 4-18.6 % for lVd and 1.6-3.3 % for hF. 6, 8, 9 analysis of more than 45,000 cases of early-stage Bc treated in woman >65 years old has shown that patients who received both trastuzumab and anthracycline had an absolute 23.8 % higher rate, and those treated with anthracycline chemotherapy alone has an absolute 2.1 % higher rate of hF or cardiomyopathy (cM) events over 3 years compared with patients who received no adjuvant chemotherapy or trastuzumab. 10 use of trastuzumab was associated with an absolute 14 % higher adjusted incidence rate for hF or cM over 3 years. 10 Furthermore, among Bc survivors >65 years old, 29.2 % were observed to have preexisting cardiovascular diseases (cVds) or diabetes at the time of diagnosis. There are some differences between anthracycline and trastuzumab cardiotoxicity: the first is irreversible, dose-related and associated with ultrastructural changes at the endomyocardial biopsy, while the second is reversible, responsive to medical therapy and does not appear to be dose related. 16, 17 What are the causes of trastuzumab's cardiotoxicity, especially in coadministration with anthracyclines? hER2 plays an important role in the HEr-neuregulin 1 axis is a critical component of the response of cardiac tissue to stress. When the heart is exposed to anthracyclines, pathways that lead to cardiomyocytes death are activated. 21 Signalling from the HEr2-HEr4 dimerisation are activated as a counter-measure, but they are blocked by trastuzumab. In view of these circumstances, there is a growing possibility of using recombinant neuregulin-1 in severe HF, which use has demonstrated to increase the lVEF of 12 %.
22
Further investigations are required to determine safety.
given these assumptions, the administration of trastuzumab after anthracyclines may be related to an increased risk of heart damage compared with the opposite sequence. clinical evidence to support this hypothesis comes from the comparison of the 0 % incidence of HF in a Finnish trial with only 9 weeks of herceptin (FinHEr) (in which trastuzumab preceded anthracyclines) and 3-4 % incidence of HF in trials where trastuzumab was given after.
5,23,24
Bevacizumab is a humanised monoclonal antibody against vascular endothelial growth factor (VEgF). the uncontrolled hypertension (discussed below) and the inhibition of VEgF signalling, both able to alter the adaptive responses of the heart, seem to be potential mechanisms able to explain its cardiotoxicity. Bevacizumab-related HF ranges from retrospective analysis of patients treated with sunitinib showed an incidence of HF from 2.7 % to 8 %. 30, 31 no change in lVEF has been reported in a trial of patients with advanced gastrointestinal stromal tumour (gISt) treated with sunitinib for 8 weeks. 32 Schmidinger et al. 33 estimate an incidence of lVEF drop of 5 % for sorafenib and 14 % for sunitinib. particular attention should be paid when patients are sequentially treated with those two drugs, as additive cardiotoxicity has been reported. 34 Sunitinib induces an intracellular signalling cascade that releases the pro-apoptotic factor Bcl2. this could induce the found rates of all-and high-grade VtE of 11.8 and 6.3 %, respectively.
the proposed mechanism for the development of ischaemic phenomena is a decrease in the regeneration process of endothelial cells during anti-VEgF treatment, through a loss of integrity of the endothelium, which allow the exposure of subendothelial collagen, activation of tissue factor and, therefore, of the coagulation cascade.
39,40
Small Molecule Tyrosine Kinase Inhibitors a higher frequency of atE have been found in patients treated with sorafenib for metastatic renal cancer (3 %) 41 compared with placebo.
choueiri et al. 42 find an incidence of 1.3 and 1.7 %, respectively, with no statistically significant difference.
Chemotherapy-related Hypertension
treatment of cancer patients with inhibitors of angiogenesis, both antibodies or tyrosine kinase inhibitors (tKIs), is commonly associated with systemic arterial hypertension, with potential organ damage.
1, 43, 44 Hypertension is a known complication of bevacizumab (VEgF inhibitor) with 4 % to 35 % of patients with raised blood pressure (Bp) during treatment and 11-18 % of patients with grade 3 hypertension, 1 of which 11-16 % require de novo treatment with antihypertensive medication, and 1 % that develop a hypertensive crisis. 44 ranpura et al. 45 found high-grade hypertension in 7.9 % of patients, without significant differences between high and low dose.
For sutinitib, incidences of all-and high-grade hypertension are 21.6 and 6.8 %, respectively, with relative risks of 3.44 and 22.72, respectively. 46 However, studies and meta-analysis used different diagnostic criteria, with a large variability of results. For example, a retrospective analysis on sunitinib 30 found that 47 % of patients developed hypertension, defined as Bp >150/100 mmHg. Sorafenib is widely associated with this adverse effect (17 % to 43 % of patients in clinical trials), often severe (grade 3 and 4 occurs in 1.4 % to 38 %). 1 Several theories have been put forward: the increased arterial resistance can be explained by the inhibition of VEgF, with a decrease of the nitrous oxide (no)-synthase activity in the arterioles and loss of the contribution of this vasodilating molecule and/or the reduction of the arteriolar and capillary density. 47, 48 In this regard, mourad et al. 49 have demonstrated that hypertension induced by bevacizumab was associated with capillary rarefaction measured by capillaroscopy.
Veronese et al. 50 found that hypertension induced by sorafenib is mainly due to an increase in vascular rigidity.
Chemotherapy-related QT Interval Prolongation
the main pro-arrhythmic adverse effect induced by anti-cancer therapy is the prolongation of the Qt interval, which is a measure of the total duration of ventricular depolarisation and repolarisation, from the beginning of the QrS complex to the end of the t wave, the duration of which is affected by the heart rate.
Multitargeted Tyrosine Kinase Inhibitors
prolongation of Qtc (Qtp) >60 msec was found in, respectively, 1.9 % and 2.5 % of patients with chronic-and accelerated-phase chronic myelogenous leukaemia treated with nilotinib, 51 while in another phase II trial, the percentage rose to 4 % (no patient had Qtc >500 msec). • cardiomyopathy in terms of a reduction in lVEF, either global or more severe in the septum;
• symptoms associated with HF;
• signs associated with HF (such as S3 gallop, tachycardia); and
• decline in lVEF of at least 5 % to less than 55 % with accompanying signs or symptoms of HF, or a decline in lVEF of at least 10 % to <55 % without accompanying signs or symptoms of HF. , and beta blockers.
non-dihydropyridine calcium channel blockers should be avoided, as they are able to interfere with cytochrome p450 and cyp3a4
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, of which the antiangiogenic drugs are a substrate. regular monitoring is recommended weekly during the first cycle of therapy, and then at least every 2 or 3 weeks for the duration of drug regimen. Discontinuation must be considered if systolic Bp is >200 mmHg or diastolic Bp >100 mmHg.
at earlier stages, discontinuation remains controversial, as grade 2 and 3 hypertension seems to be associated with a good response to therapy 63 and it is important to allow continuous and safe administration of VEgFtarget drugs without dose modification. treatment with bevacizumab has been associated with proteinuria in patients who develop hypertension (up to 41-63 %), 64 with a causal and dose-dependent relationship. recommendations. However, a retrospective study on aspirin and beta blockers in patients with cancer and acS showed an improved 7-day survival rate without increasing of the bleeding risk. 65 
Management of Myocardial Ischaemia

Management of QT Prolongation
Qt prolongation is a commune-adverse effect of many drugs (see www. 68 shows that 10 % of patients experienced a decline in lVEF >10 %, yet still more than 50 %.
However, longitudinal 2DStE decreased significantly at 3 months and systolic strain rate by tDI decreased at 6 months, suggesting evidence of occult lVD associated with therapy with trastuzumab despite preserved lVEF, proving that these two techniques are more sensitive in detecting occult lVD. 69 For further evidence, a recent prospective study by Fallahrad et al., 70 showed that 25 % of patients treated in the same way who developed cardiotoxicity (decrease in lVEF >10 % or a value <55 % with signs or symptoms of HF) showed lVEF variations at 6 months after therapy with trastuzumab; however, after 3 months the peak systolic velocity of the side wall (S') to the tDI and global peak longitudinal and radial strain by 2DStE had already declined, proving indices of early systolic dysfunction.
Systolic and diastolic function should be assessed at baseline, before and during treatment with monoclonal antibodies or anthracyclines.
Further evaluations, through conventional methods, tDI and 2DStE are recommended, even in asymptomatic patients.
patients with lVD should be evaluated by coronary angiography or dobutamine stress echocardiography to exclude coronary artery disease, which could lead to specific treatment.
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Biomarkers in Evaluation of Cardiotoxicity
troponin is the gold standard for detection of myocardial ischaemia and damage: increased levels has been observed in patients treated with standard dose of anthracyclines and with the newly targeted therapies.
Detemination of troponin levels can be useful to identify patients at risk for HF and to discriminate between reversible and irreversible cardiac damage in Bc survivors treated with trastuzumab. 71 periodic assessment of troponin levels during high-dose chemotherapy allows the identification of patients at risk of cardiac dysfunction and cardiac risk stratification, proving as an early predictor of lVD and subsequent reduction in lVEF. 72 Sawaya et al. 73 have combined biomarkers with echocardiography in a multicentre study of patients treated with anthracyclines and trastuzumab, which showed that a decrease in longitudinal and radial strain and the elevation of troponin at 3 months is predictor of reduction in lVEF at 6 months.
B-type natriuretic peptide (Bnp) is a cardiac hormone released by the myocardium in response to volume overload, so increased levels of
Bnp reflects an augmentation of the filling pressure and lVD. a useful approach, but still controversial, is performing the basic assessment of these biomarkers and periodic measurements during therapy to identify patients who require further cardiac evaluation. patients who develop lVD with lVEF <50 % or a decline of >10 % should discontinue anti-cancer therapy and must be treated at first-line with an acE-In and a beta-blocker. 77 
